Want to see KR:001060 full AI Analyst Report?

JW Pharmaceutical Corporation (001060) Price & Analysis

― Followers

001060 Stock Chart & Stats

$23200.00

$50.00(0.22%)

Oct 28, 2026

―

Day’s Range― - ―

52-Week Range$21,550.00 - $39,250.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)31.71K

Market Cap

₩560.29B

Enterprise Value$603.48B

Total Cash (Recent Filing)₩59.65B

Total Debt (Recent Filing)₩71.75B

Price to Earnings (P/E)5.5

Beta0.36

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.8%

Share Statistics

EPS (TTM)4192.84

Shares Outstanding24,581,533

10 Day Avg. Volume33,315

30 Day Avg. Volume31,711

Financial Highlights & Ratios

PEG Ratio-2.42

Price to Book (P/B)1.67

Price to Sales (P/S)0.79

P/FCF Ratio7.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)3,670

Revenue Forecast (FY)₩849.20B

Bulls Say, Bears Say

Bulls Say

Improving ProfitabilityProfitability has improved materially from the lower margins reported in prior years, with strong TTM net, EBIT, and EBITDA margins. This indicates better earnings quality and provides a stronger base for reinvestment, resilience, and sustained returns over the coming quarters.

Conservative LeverageThe sharp reduction in debt-to-equity gives JW Pharmaceutical greater financial flexibility and reduces the burden of interest and refinancing needs. Combined with a high TTM ROE, the balance sheet indicates effective capital use and capacity to support operations through changing conditions.

Robust Cash GenerationStrong operating and free cash flow shows that reported profits are converting into usable cash, supporting internal funding for products, investment, and shareholder returns. The high TTM conversion ratio also strengthens financial resilience and reduces reliance on external financing.

Bears Say

Uneven Revenue GrowthRevenue growth has not been consistently strong across the reported period, including a decline in 2024 and only steady TTM expansion. This uneven top-line trajectory may limit operating leverage and makes sustained profit growth more dependent on margins rather than broad-based demand growth.

Moderate Debt Cash CoverageAlthough leverage is currently conservative, operating cash flow relative to total debt remains only moderate, and historical cash conversion was weaker. Continued improvement is important because inconsistent cash coverage could constrain funding flexibility if borrowing rises or profitability normalizes.

Concentrated OwnershipThe increased ownership concentration strengthens the controlling shareholder’s influence and may reduce minority investors’ ability to affect governance or capital-allocation decisions. Simplifying the capital structure can help clarity, but concentrated control may constrain flexibility for future capital raising.

JW Pharmaceutical Corporation News

JW Holdings Boosts Common Share Control at JW Pharmaceutical Through Preferred Share Conversion

JW Pharmaceutical Corporation ( ($KR:001060) ) just unveiled an announcement. JW Pharmaceutical’s largest shareholder, JW Holdings Co., Ltd.,...

1M ago

001060 FAQ

What was JW Pharmaceutical Corporation’s price range in the past 12 months?

JW Pharmaceutical Corporation lowest stock price was $21550.00 and its highest was $39250.00 in the past 12 months.

What is JW Pharmaceutical Corporation’s market cap?

JW Pharmaceutical Corporation’s market cap is ₩560.29B.

When is JW Pharmaceutical Corporation’s upcoming earnings report date?

JW Pharmaceutical Corporation’s upcoming earnings report date is Nov 18, 2026 which is in 20 days.

How were JW Pharmaceutical Corporation’s earnings last quarter?

JW Pharmaceutical Corporation released its earnings results on Aug 14, 2026. The company reported $1154.591 earnings per share for the quarter.

Is JW Pharmaceutical Corporation overvalued?

According to Wall Street analysts JW Pharmaceutical Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does JW Pharmaceutical Corporation pay dividends?

JW Pharmaceutical Corporation pays a Notavailable dividend of $650 which represents an annual dividend yield of 2.8%. See more information on JW Pharmaceutical Corporation dividends here

What is JW Pharmaceutical Corporation’s EPS estimate?

JW Pharmaceutical Corporation’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does JW Pharmaceutical Corporation have?

JW Pharmaceutical Corporation has 24,581,533 shares outstanding.

What happened to JW Pharmaceutical Corporation’s price movement after its last earnings report?

JW Pharmaceutical Corporation reported an EPS of $1154.591 in its last earnings report. Following the earnings report the stock price went up 1.228%.

Which hedge fund is a major shareholder of JW Pharmaceutical Corporation?

Currently, no hedge funds are holding shares in KR:001060

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

JW Pharmaceutical Corporation

JW Pharmaceutical Corporation, established in 1945 and headquartered in Seoul, South Korea, operates globally, focusing on the development, manufacturing, and distribution of a comprehensive range of pharmaceuticals and medical supplies. Its diverse product portfolio addresses numerous therapeutic areas, including cardiovascular, gastrointestinal, urinary, and metabolic health, as well as infectious diseases, women's health, renal and central nervous system disorders, anti-anemic treatments, respiratory ailments, rheumatic arthritis, oncology, anesthesia, antidotes, and advanced nutritional support.